---
schema_version: "secwatch.filing_event.v1"
accession: "0001404644-26-000046"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2026-06-29T12:00:50+00:00"
generated_at: "2026-06-29T12:05:22.269963+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Neurogene reports positive Phase 1/2 data for NGN-401 in Rett syndrome; 47 milestones gained across 10 patients

## Summary
- 47 developmental milestones gained across 10 participants (avg 4.7); 100% improved CGI-I and gained ≥1 milestone.
- Durable effect through 30 months with no plateau or milestone loss; median time to first improvement 2 months.
- NGN-401 generally well-tolerated; no new treatment-related SAEs since Oct 2025; all AEs mild or moderate.
- Dosing complete in Embolden registrational trial; no treatment-related SAEs or DLTs; topline data expected 2H 2027.
- Improvements across RSGMS and RSHFS scales (p<0.001); 7/10 gained ≥2 milestones across ≥2 Rett domains.

## SEC filing metadata
- accession: 0001404644-26-000046
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2026-06-29T12:00:50+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000046/0001404644-26-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000046/ngne-20260629.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001404644-26-000046
- JSON: https://secwatch.observer/filing/0001404644-26-000046.json
- Plain text: https://secwatch.observer/filing/0001404644-26-000046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.